- Global Pharma News & Resources

Influenza Diagnostics Market Dynamics, Current Trends, Advanced Share, Business Overview, Key Company Profiles, Competitive Analysis, and Forecast to 2027

Influenza, commonly known as flu, is an infectious disease caused by influenza virus. Its symptoms can be mild to severe including runny nose, high fever, muscle and joints pain, headache, coughing, fatigue, and sore throat. There are two types of influenza namely pandemic and seasonal. Furthermore, seasonal influenza is divided into influenza A, B, and C. It is contagious in nature and is transmitted from public places through sneeze and droplets of infected person who serve as a carrier of the disease. According to the Centers for Disease Control and Prevention (CDC), in the U.S., influenza resulted in 49 million symptomatic illnesses and 79,000 deaths in 2017-2018. High risk of influenza infection is observed in pregnant women, pediatrics, geriatrics, patients with low immunity that suffer from chronic illness, and healthcare professionals.

Request Sample Copy of the Business Report:

Global Influenza Diagnostics Market – Dynamics

Growing prevalence of influenza and increasing research funding for influenza diagnostics are expected to drive growth of the global influenza diagnostics market during the forecast period. According to the World Health Organization (WHO), influenza is expected to result in around 3 to 5 million cases of severe illness and around 290,000 to 650,000 deaths in 2018 worldwide. In 2014, National Institute of Allergy and Infectious Disease (NIAID) collaborated with The National Institutes of Health (NIH) Autoimmune Disease Coordinating Committee (ADCC) and supports The Center of Excellence in Influenza Research and Surveillance (CIERS) to advance the understanding of influenza virus. Furthermore, high geriatric population, which is prone to influenza, growing awareness regarding the disease coupled with high demand for advanced and more efficient influenza diagnostic tests are expected to propel the global influenza diagnostics market over the forecast period.

Global Influenza Diagnostics Market – Regional insights

Among regions, North America accounted for the largest market share in the global influenza diagnostics market. This is owing to proactive initiatives by CDC to control the spread of the disease by actively implementing preventive measures and recognizing the disease through its National Influenza Surveillance System. Moreover, increasing availability of Rapid Diagnostic Tests (RDTs) in the U.S. is expected to drive the regional market growth in the near future.

Tailored Information as per niche requirement:

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @

Furthermore, Asia Pacific is expected to register rapid growth in the global influenza diagnostics market during the forecast period. This growth is attributed to active participation of countries for preventive measures to counter the incidence of the influenza. For instance, in 2014, CDC funded nine non-researched-related bilateral influenza cooperative agreement in South-East Asian Region (SEAR), as a measure to respond to avian, seasonal, and pandemic influenza.

Global Influenza Diagnostic Market – Competitive landscape

Major players operating in the global influenza diagnostic market are, Roche Diagnostics, Becton, Dickinson and Company, Thermo Fisher Scientific, Alere, Quidel Corporation, and others.

Major companies in the market are adopting various growth strategies such as gaining product approvals, in order to enhance their global market presence. For instance, in 2016, Roche received the U.S. Food and Drug Administration (FDA) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver for its cobas Influenza A/B & RSV test. The test is used with the cobas Liat system and assists in molecular testing of flu A/B and RSV.

Key Development 

Key players in the market are involved in various business strategies such as product launch, product approval, and acquisitions, in order to gain competitive edge in the market.

  • In February 2019, Abbott Laboratories launched reformulated BinaxNow A & B Card 2 rapid Influenza test. BinaxNow A & B Card 2, which is an in vitro immunochromatographic assay for the detection of influenza.
  • In February 2019, Eurofins Viracor, Inc., has introduced aloxavir marboxil (XOFLUZA) Influenza which is an Antiviral Resistance PCR test for the detection of I38T/M/F mutations in H3N2.
  • In 2018, Sekisui Diagnostics launched Silaris Influenza A&B test in collaboration with Mesa Biotech, Inc.
  • In 2018, Abbott Laboratories, acquired Alere Inc., a diagnostic device and service provide, which strengthened the company’s diagnostics presence in the global market.
  • In 2016, Roche received the U.S. FDA clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver for its real-time PCR test, cobas Influenza A/B & RSV test. The test is used with the cobas Liat system and assists in molecular testing of flu A/B and RSV

To understand Research Methodology, please click

Global Influenza Diagnostics Market Taxonomy:

On the basis of test type, the global influenza diagnostics market is segmented into:

  • Traditional Diagnostic Tests
    • Rapid Influenza Diagnostic Tests (RIDT)
    • Viral Culture
    • Direct Fluorescent Antibody (DFA) Tests
    • Serological Assays
  • Molecular Diagnostic Assays
    • RT-PCR
    • Nucleic Acid Sequence-Based Amplification (NASBA) Tests
    • Loop-Mediated Isothermal Amplification-Based Assays (LAMP)
    • Simple Amplification-Based Assays (SAMBA)
    • Others

On the basis of end-user, the global influenza diagnostics market is segmented into:

  • Hospitals & Clinics
  • Reference Laboratories
  • Others

On the basis of regions, the global influenza diagnostics market is segmented into:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website –


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 05-Feb-2021